Global and Japan Hematologic Malignancies Market Size, Status and Forecast 2020-2026
Table of Contents1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hematologic Malignancies Market Size Growth Rate by Type: 2020 VS 2026
1.2.2 Leukemia
1.2.3 Lymphoma
1.2.4 Multiple Myeloma
1.2.5 Others
1.3 Market by Application
1.3.1 Global Hematologic Malignancies Market Share by Application: 2020 VS 2026
1.3.2 Chemotherapy
1.3.3 Radiotherapy
1.3.4 Immunotherapy
1.3.5 Stem Cell Transplantation
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Hematologic Malignancies Market Perspective (2015-2026)
2.2 Global Hematologic Malignancies Growth Trends by Regions
2.2.1 Hematologic Malignancies Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Hematologic Malignancies Historic Market Share by Regions (2015-2020)
2.2.3 Hematologic Malignancies Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hematologic Malignancies Players by Market Size
3.1.1 Global Top Hematologic Malignancies Players by Revenue (2015-2020)
3.1.2 Global Hematologic Malignancies Revenue Market Share by Players (2015-2020)
3.2 Global Hematologic Malignancies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Hematologic Malignancies Revenue
3.4 Global Hematologic Malignancies Market Concentration Ratio
3.4.1 Global Hematologic Malignancies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hematologic Malignancies Revenue in 2019
3.5 Key Players Hematologic Malignancies Area Served
3.6 Key Players Hematologic Malignancies Product Solution and Service
3.7 Date of Enter into Hematologic Malignancies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hematologic Malignancies Breakdown Data by Type (2015-2026)
4.1 Global Hematologic Malignancies Historic Market Size by Type (2015-2020)
4.2 Global Hematologic Malignancies Forecasted Market Size by Type (2021-2026)
5 Hematologic Malignancies Breakdown Data by Application (2015-2026)
5.1 Global Hematologic Malignancies Historic Market Size by Application (2015-2020)
5.2 Global Hematologic Malignancies Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Hematologic Malignancies Market Size (2015-2026)
6.2 North America Hematologic Malignancies Market Size by Type (2015-2020)
6.3 North America Hematologic Malignancies Market Size by Application (2015-2020)
6.4 North America Hematologic Malignancies Market Size by Country (2015-2020)
6.4.1 United States
6.4.2 Canada
7 Europe
7.1 Europe Hematologic Malignancies Market Size (2015-2026)
7.2 Europe Hematologic Malignancies Market Size by Type (2015-2020)
7.3 Europe Hematologic Malignancies Market Size by Application (2015-2020)
7.4 Europe Hematologic Malignancies Market Size by Country (2015-2020)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
7.4.6 Nordic
7.4.7 Rest of Europe
8 China
8.1 China Hematologic Malignancies Market Size (2015-2026)
8.2 China Hematologic Malignancies Market Size by Type (2015-2020)
8.3 China Hematologic Malignancies Market Size by Application (2015-2020)
8.4 China Hematologic Malignancies Market Size by Region (2015-2020)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 Southeast Asia
8.4.5 India
8.4.6 Australia
8.4.7 Rest of Asia-Pacific
9 Japan
9.1 Japan Hematologic Malignancies Market Size (2015-2026)
9.2 Japan Hematologic Malignancies Market Size by Type (2015-2020)
9.3 Japan Hematologic Malignancies Market Size by Application (2015-2020)
9.4 Japan Hematologic Malignancies Market Size by Country (2015-2020)
9.4.1 Mexico
9.4.2 Brazil
10 Southeast Asia
10.1 Southeast Asia Hematologic Malignancies Market Size (2015-2026)
10.2 Southeast Asia Hematologic Malignancies Market Size by Type (2015-2020)
10.3 Southeast Asia Hematologic Malignancies Market Size by Application (2015-2020)
10.4 Southeast Asia Hematologic Malignancies Market Size by Country (2015-2020)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 UAE
10.4.4 Rest of Middle East & Africa
11 Key Players Profiles
11.1 Pfizer, Inc.
11.1.1 Pfizer, Inc. Company Details
11.1.2 Pfizer, Inc. Business Overview
11.1.3 Pfizer, Inc. Hematologic Malignancies Introduction
11.1.4 Pfizer, Inc. Revenue in Hematologic Malignancies Business (2015-2020))
11.1.5 Pfizer, Inc. Recent Development
11.2 F. Hoffmann-LA Roche ltd
11.2.1 F. Hoffmann-LA Roche ltd Company Details
11.2.2 F. Hoffmann-LA Roche ltd Business Overview
11.2.3 F. Hoffmann-LA Roche ltd Hematologic Malignancies Introduction
11.2.4 F. Hoffmann-LA Roche ltd Revenue in Hematologic Malignancies Business (2015-2020)
11.2.5 F. Hoffmann-LA Roche ltd Recent Development
11.3 Sanofi-Aventis
11.3.1 Sanofi-Aventis Company Details
11.3.2 Sanofi-Aventis Business Overview
11.3.3 Sanofi-Aventis Hematologic Malignancies Introduction
11.3.4 Sanofi-Aventis Revenue in Hematologic Malignancies Business (2015-2020)
11.3.5 Sanofi-Aventis Recent Development
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Details
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Hematologic Malignancies Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Hematologic Malignancies Business (2015-2020)
11.4.5 Bristol-Myers Squibb Company Recent Development
11.5 AbbVie, Inc.
11.5.1 AbbVie, Inc. Company Details
11.5.2 AbbVie, Inc. Business Overview
11.5.3 AbbVie, Inc. Hematologic Malignancies Introduction
11.5.4 AbbVie, Inc. Revenue in Hematologic Malignancies Business (2015-2020)
11.5.5 AbbVie, Inc. Recent Development
11.6 Novartis AG
11.6.1 Novartis AG Company Details
11.6.2 Novartis AG Business Overview
11.6.3 Novartis AG Hematologic Malignancies Introduction
11.6.4 Novartis AG Revenue in Hematologic Malignancies Business (2015-2020)
11.6.5 Novartis AG Recent Development
11.7 GlaxoSmithKline PLC
11.7.1 GlaxoSmithKline PLC Company Details
11.7.2 GlaxoSmithKline PLC Business Overview
11.7.3 GlaxoSmithKline PLC Hematologic Malignancies Introduction
11.7.4 GlaxoSmithKline PLC Revenue in Hematologic Malignancies Business (2015-2020)
11.7.5 GlaxoSmithKline PLC Recent Development
11.8 Celgene Corporation
11.8.1 Celgene Corporation Company Details
11.8.2 Celgene Corporation Business Overview
11.8.3 Celgene Corporation Hematologic Malignancies Introduction
11.8.4 Celgene Corporation Revenue in Hematologic Malignancies Business (2015-2020)
11.8.5 Celgene Corporation Recent Development
11.9 Johnson & Johnson Services, Inc.
11.9.1 Johnson & Johnson Services, Inc. Company Details
11.9.2 Johnson & Johnson Services, Inc. Business Overview
11.9.3 Johnson & Johnson Services, Inc. Hematologic Malignancies Introduction
11.9.4 Johnson & Johnson Services, Inc. Revenue in Hematologic Malignancies Business (2015-2020)
11.9.5 Johnson & Johnson Services, Inc. Recent Development
11.10 Takeda Pharmaceutical Company limited
11.10.1 Takeda Pharmaceutical Company limited Company Details
11.10.2 Takeda Pharmaceutical Company limited Business Overview
11.10.3 Takeda Pharmaceutical Company limited Hematologic Malignancies Introduction
11.10.4 Takeda Pharmaceutical Company limited Revenue in Hematologic Malignancies Business (2015-2020)
11.10.5 Takeda Pharmaceutical Company limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesTable 1. Global Hematologic Malignancies Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 3. Key Players of Leukemia
Table 4. Key Players of Lymphoma
Table 5. Key Players of Multiple Myeloma
Table 6. Key Players of Others
Table 7. Global Hematologic Malignancies Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Hematologic Malignancies Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Hematologic Malignancies Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Hematologic Malignancies Market Share by Regions (2015-2020)
Table 11. Global Hematologic Malignancies Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Hematologic Malignancies Market Share by Regions (2021-2026)
Table 13. Hematologic Malignancies Market Market Trends
Table 14. Hematologic Malignancies Market Drivers
Table 15. Hematologic Malignancies Market Challenges
Table 16. Hematologic Malignancies Market Restraints
Table 17. Global Hematologic Malignancies Revenue by Players (2015-2020) (US$ Million)
Table 18. Global Hematologic Malignancies Market Share by Players (2015-2020)
Table 19. Global Top Hematologic Malignancies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematologic Malignancies as of 2019)
Table 20. Global Hematologic Malignancies by Players Market Concentration Ratio (CR5 and HHI)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Hematologic Malignancies Product Solution and Service
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Hematologic Malignancies Market Size by Type (2015-2020) (US$ Million)
Table 25. Global Hematologic Malignancies Market Size Share by Type (2015-2020)
Table 26. Global Hematologic Malignancies Revenue Market Share by Type (2021-2026)
Table 27. Global Hematologic Malignancies Market Size Share by Application (2015-2020)
Table 28. Global Hematologic Malignancies Market Size by Application (2015-2020) (US$ Million)
Table 29. Global Hematologic Malignancies Market Size Share by Application (2021-2026)
Table 30. North America Hematologic Malignancies Market Size by Type (2015-2020) (US$ Million)
Table 31. North America Hematologic Malignancies Market Share by Type (2015-2020)
Table 32. North America Hematologic Malignancies Market Size by Application (2015-2020) (US$ Million)
Table 33. North America Hematologic Malignancies Market Share by Application (2015-2020)
Table 34. North America Hematologic Malignancies Market Size by Country (US$ Million) (2015-2020)
Table 35. North America Hematologic Malignancies Market Share by Country (2015-2020)
Table 36. Europe Hematologic Malignancies Market Size by Type (2015-2020) (US$ Million)
Table 37. Europe Hematologic Malignancies Market Share by Type (2015-2020)
Table 38. Europe Hematologic Malignancies Market Size by Application (2015-2020) (US$ Million)
Table 39. Europe Hematologic Malignancies Market Share by Application (2015-2020)
Table 40. Europe Hematologic Malignancies Market Size by Country (US$ Million) (2015-2020)
Table 41. Europe Hematologic Malignancies Market Share by Country (2015-2020)
Table 42. China Hematologic Malignancies Market Size by Type (2015-2020) (US$ Million)
Table 43. China Hematologic Malignancies Market Share by Type (2015-2020)
Table 44. China Hematologic Malignancies Market Size by Application (2015-2020) (US$ Million)
Table 45. China Hematologic Malignancies Market Share by Application (2015-2020)
Table 46. China Hematologic Malignancies Market Size by Region (US$ Million) (2015-2020)
Table 47. China Hematologic Malignancies Market Share by Region (2015-2020)
Table 48. Japan Hematologic Malignancies Market Size by Type (2015-2020) (US$ Million)
Table 49. Japan Hematologic Malignancies Market Share by Type (2015-2020)
Table 50. Japan Hematologic Malignancies Market Size by Application (2015-2020) (US$ Million)
Table 51. Japan Hematologic Malignancies Market Share by Application (2015-2020)
Table 52. Japan Hematologic Malignancies Market Size by Country (US$ Million) (2015-2020)
Table 53. Japan Hematologic Malignancies Market Share by Country (2015-2020)
Table 54. Southeast Asia Hematologic Malignancies Market Size by Type (2015-2020) (US$ Million)
Table 55. Southeast Asia Hematologic Malignancies Market Share by Type (2015-2020)
Table 56. Southeast Asia Hematologic Malignancies Market Size by Application (2015-2020) (US$ Million)
Table 57. Southeast Asia Hematologic Malignancies Market Share by Application (2015-2020)
Table 58. Southeast Asia Hematologic Malignancies Market Size by Country (US$ Million) (2015-2020)
Table 59. Southeast Asia Hematologic Malignancies Market Share by Country (2015-2020)
Table 60. Pfizer, Inc. Company Details
Table 61. Pfizer, Inc. Business Overview
Table 62. Pfizer, Inc. Product
Table 63. Pfizer, Inc. Revenue in Hematologic Malignancies Business (2015-2020) (US$ Million)
Table 64. Pfizer, Inc. Recent Development
Table 65. F. Hoffmann-LA Roche ltd Company Details
Table 66. F. Hoffmann-LA Roche ltd Business Overview
Table 67. F. Hoffmann-LA Roche ltd Product
Table 68. F. Hoffmann-LA Roche ltd Revenue in Hematologic Malignancies Business (2015-2020) (US$ Million)
Table 69. F. Hoffmann-LA Roche ltd Recent Development
Table 70. Sanofi-Aventis Company Details
Table 71. Sanofi-Aventis Business Overview
Table 72. Sanofi-Aventis Product
Table 73. Sanofi-Aventis Revenue in Hematologic Malignancies Business (2015-2020) (US$ Million)
Table 74. Sanofi-Aventis Recent Development
Table 75. Bristol-Myers Squibb Company Company Details
Table 76. Bristol-Myers Squibb Company Business Overview
Table 77. Bristol-Myers Squibb Company Product
Table 78. Bristol-Myers Squibb Company Revenue in Hematologic Malignancies Business (2015-2020) (US$ Million)
Table 79. Bristol-Myers Squibb Company Recent Development
Table 80. AbbVie, Inc. Company Details
Table 81. AbbVie, Inc. Business Overview
Table 82. AbbVie, Inc. Product
Table 83. AbbVie, Inc. Revenue in Hematologic Malignancies Business (2015-2020) (US$ Million)
Table 84. AbbVie, Inc. Recent Development
Table 85. Novartis AG Company Details
Table 86. Novartis AG Business Overview
Table 87. Novartis AG Product
Table 88. Novartis AG Revenue in Hematologic Malignancies Business (2015-2020) (US$ Million)
Table 89. Novartis AG Recent Development
Table 90. GlaxoSmithKline PLC Company Details
Table 91. GlaxoSmithKline PLC Business Overview
Table 92. GlaxoSmithKline PLC Product
Table 93. GlaxoSmithKline PLC Revenue in Hematologic Malignancies Business (2015-2020) (US$ Million)
Table 94. GlaxoSmithKline PLC Recent Development
Table 95. Celgene Corporation Business Overview
Table 96. Celgene Corporation Product
Table 97. Celgene Corporation Company Details
Table 98. Celgene Corporation Revenue in Hematologic Malignancies Business (2015-2020) (US$ Million)
Table 99. Celgene Corporation Recent Development
Table 100. Johnson & Johnson Services, Inc. Company Details
Table 101. Johnson & Johnson Services, Inc. Business Overview
Table 102. Johnson & Johnson Services, Inc. Product
Table 103. Johnson & Johnson Services, Inc. Revenue in Hematologic Malignancies Business (2015-2020) (US$ Million)
Table 104. Johnson & Johnson Services, Inc. Recent Development
Table 105. Takeda Pharmaceutical Company limited Company Details
Table 106. Takeda Pharmaceutical Company limited Business Overview
Table 107. Takeda Pharmaceutical Company limited Product
Table 108. Takeda Pharmaceutical Company limited Revenue in Hematologic Malignancies Business (2015-2020) (US$ Million)
Table 109. Takeda Pharmaceutical Company limited Recent Development
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of FiguresFigure 1. Global Hematologic Malignancies Market Share by Type: 2020 VS 2026
Figure 2. Leukemia Features
Figure 3. Lymphoma Features
Figure 4. Multiple Myeloma Features
Figure 5. Others Features
Figure 6. Global Hematologic Malignancies Market Share by Application: 2020 VS 2026
Figure 7. Chemotherapy Case Studies
Figure 8. Radiotherapy Case Studies
Figure 9. Immunotherapy Case Studies
Figure 10. Stem Cell Transplantation Case Studies
Figure 11. Others Case Studies
Figure 12. Hematologic Malignancies Report Years Considered
Figure 13. Global Hematologic Malignancies Market Size (US$ Million), YoY Growth 2015-2026
Figure 14. Global Hematologic Malignancies Market Share by Regions: 2020 VS 2026
Figure 15. Global Hematologic Malignancies Market Share by Regions (2021-2026)
Figure 16. Global Hematologic Malignancies Market Share by Players in 2019
Figure 17. Global Top Hematologic Malignancies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematologic Malignancies as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Hematologic Malignancies Revenue in 2019
Figure 19. North America Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 20. United States Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 21. Canada Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 22. Europe Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 23. Germany Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 24. France Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 25. U.K. Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 26. Italy Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 27. Russia Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 28. Nordic Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 29. Rest of Europe Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 30. Asia-Pacific Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 31. China Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 32. Japan Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 33. South Korea Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 34. Southeast Asia Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 35. India Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 36. Australia Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 37. Rest of Asia-Pacific Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 38. Latin America Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 39. Mexico Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 40. Brazil Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 41. Middle East & Africa Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 42. Turkey Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 43. Saudi Arabia Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 44. UAE Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 45. Rest of Middle East & Africa Hematologic Malignancies Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 46. Pfizer, Inc. Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 47. F. Hoffmann-LA Roche ltd Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 48. Sanofi-Aventis Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 49. Bristol-Myers Squibb Company Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 50. AbbVie, Inc. Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 51. Novartis AG Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 52. GlaxoSmithKline PLC Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 53. Celgene Corporation Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 54. Johnson & Johnson Services, Inc. Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 55. Takeda Pharmaceutical Company limited Revenue Growth Rate in Hematologic Malignancies Business (2015-2020)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed